{"name":"Praxis Precision Medicines","slug":"praxis-precision-medicines","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":3,"colorKey":"oncology","drugs":[{"name":"PRAX-222 - Fixed Doses","genericName":"PRAX-222 - Fixed Doses","slug":"prax-222-fixed-doses","indication":"Other","status":"phase_1"},{"name":"PRAX-628","genericName":"PRAX-628","slug":"prax-628","indication":"Other","status":"phase_1"},{"name":"vormatrogine","genericName":"vormatrogine","slug":"vormatrogine","indication":"Other","status":"phase_3"}]}],"pipeline":[{"name":"PRAX-222 - Fixed Doses","genericName":"PRAX-222 - Fixed Doses","slug":"prax-222-fixed-doses","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"PRAX-628","genericName":"PRAX-628","slug":"prax-628","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"vormatrogine","genericName":"vormatrogine","slug":"vormatrogine","phase":"phase_3","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMihgFBVV95cUxPMXhtV2tzSHNkWDJrSVBmbG4yZUQtcjdtMkJSbk8ybVJXdFZER3lxdnU0RUp0ODE2Vk84WG5DRVg2MldxVHRza2ZURkVCYlBfbEV6NjROS1h5RFE2WGxkdEJnR2tPTnZqNTZ4bEdkdGMtcDFhU2RNSGtpWUxSdGVnYXJtNnIwUQ?oc=5","date":"2026-02-02","type":"deal","source":"Contract Pharma","summary":"SEQSTER, Praxis Extend Partnership - Contract Pharma","headline":"SEQSTER, Praxis Extend Partnership","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiiAFBVV95cUxPbjRqeVFJazA4RlI4cC1QaXhwZHdoNjFIcThCckNlZ2xfc2NrLXp0SnhodmdkUFFZN05EWVJSbll2VDl5RUNEVjduWmVNOXlqV1hBM3R3OHBSZWp5M09pdjlFM2lYRV92aHlmNmNoMVBKYzhaNW5GTzhNRzNTSHdFaC1kb1FWMl92?oc=5","date":"2026-02-02","type":"pipeline","source":"Fierce Pharma","summary":"Top 10 most anticipated drug launches of 2026 - Fierce Pharma","headline":"Top 10 most anticipated drug launches of 2026","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijwFBVV95cUxPVHBiSWJKMXdiWU1XUjlTb2t5MTlJc0lWcnRTT0NlLV9QTzNFUk1hcmVXWFQzQURCU2xWRkJfU0E3OFNRZ0t5MEh3SUR6bzBzZGU5dmJqODJhNV9yT3ZYRnpwTlNDelNucjE2ZGh4a3V0WHp0cDhvS3ViTFJtR3dzenFHUVp6QU1hOGtQaXNadw?oc=5","date":"2026-01-06","type":"pipeline","source":"Yahoo Finance","summary":"Praxis Precision Medicines, Inc. Announces Pricing of $575 Million Public Offering - Yahoo Finance","headline":"Praxis Precision Medicines, Inc. Announces Pricing of $575 Million Public Offering","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijAFBVV95cUxPUXg0VXlWdzRuaHlHNXkwcWVIcnh2MG9OdTg5VWJUQm5GMmh6WGJuMl9WX1c3dFFYUkNjOEl3eUF2QzNMQmFfa1JUaE13aU5URjY2dnJZOXFlZFdHeU1GNXV4VE9PUFpWc1UxcnNsR2tkWjRrUEFibmliY2pkNDBjcW5vYzAwZ016MjRlcg?oc=5","date":"2025-12-06","type":"regulatory","source":"The Pharma Letter","summary":"Praxis sets up CNS drug approval in 2026 - The Pharma Letter","headline":"Praxis sets up CNS drug approval in 2026","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMilwFBVV95cUxOdnJOQm40YXhBNVFZN1pBWWs3dUhaemZQbXJFb243TnB0QWd0N2x4b0dydTVOcEV6cnY4R3dwRXhlTGtLbTlqNFc2ZU9LSWM3WHRreVBERlVEMXg4M00weVdWakRqT3dUR0RkSEVITjBpbDhrZ0xuRTVkYXBWNkdhcmVZbTBWWjNBd0o5Qjg0Rm1nZFpXRDBB?oc=5","date":"2025-12-05","type":"pipeline","source":"Investor's Business Daily","summary":"The Surprise That Sent This Stock To Another 3-Year High - Investor's Business Daily","headline":"The Surprise That Sent This Stock To Another 3-Year High - Investor's Business Daily","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi4AFBVV95cUxNZ0JicHVjcjdkUkdDZ3BvSWU1U1lUMHpwZFMzZTh0V1NLeXhHQW9DOVN3bDhFQ3Y3M3hhV3g4QURUamFVSkIxQnppdzg1SDJ0VE52dzE4MHBMUnFGa1pMQWxqaUR4amtOOUlqZjFiVVFmRnN6UkFIVzZvSDQ4YnBGVFZ2VWd4ZGJqNW9ReW1PV1V4ZUNQSkN5dktpQktjbTJHMjVwcnIyNklyZkc4d3Fwb1VsTGZENEMxYnV6N3NySFFCbElpQTZxODYzMlMwWVo2Mk04Z1k2RXZqbUxnSjgtTA?oc=5","date":"2025-11-20","type":"pipeline","source":"Stocktwits","summary":"Praxis Precision Medicines Stock Drops After Culper Research Reveals Short Position - Stocktwits","headline":"Praxis Precision Medicines Stock Drops After Culper Research Reveals Short Position","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiogFBVV95cUxOSXRPNnJXMmtJQl82Y2lGYzBUOFRLXzFZWEFBTEtoZ0o1V0lRa0JsNlRWNlJqTFZIcW8tYmNXMkxVR1FXMUZsYlQ2ZDJWbVQ0cm1VUUdOXzdoTU10RUR6VFR1bUFZdWZjd0NtUkxMVHhpSmJDMkpOQ3FoWXpoMUVuUTF4Q2toZnpJb1hYdG5Jb2JWTHNkal9rSlVNVkI3cy1wMUE?oc=5","date":"2025-10-16","type":"pipeline","source":"BioPharma Dive","summary":"A longshot bet on a tremor drug pays off - BioPharma Dive","headline":"A longshot bet on a tremor drug pays off","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihAFBVV95cUxPNjJzVzZSWVhzbWltbk1MU2hVQXJ3cE9iV0V6bk9DamMzVnBwTUN4WXdhNnE2d2JPVUJwdFBpdVQwR3BYWGR1TkY0Ynk1VWNjdHd6ekEwcUxxUUtxSUpFazExNWJtM0F5bzJOa2l6VWpydXNyRk9zazFhMDRnNXpqa0VLV0Y?oc=5","date":"2025-10-16","type":"pipeline","source":"Barron's","summary":"Praxis Precision Medicines’ Tremor Treatment is Back From the Dead. The Stock Is Up 200% - Barron's","headline":"Praxis Precision Medicines’ Tremor Treatment is Back From the Dead. The Stock Is Up 200% - Barron's","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwAFBVV95cUxQZkZuWkVVZDQxMG1sRjVlaHViXzEtX0xqaGVmMGFzdkwzd1ExMWEwUDQ3WHh3aVdCMVNLZHl6ZVdXWUpZNmtiZTc4NFE1UHVyeXBiQ2ptaTJLQ1d0dEJEaFdDVGlsZFJTTWpfdmlkY2dKWWQ0a3RKSWZHNFlqSTdSZkozYjRkSG45Q0VwMmhjU3h3M3BLLU1XX0hsYTNiX1N2QVBEX0FsbF9kZmFLNzdMUnRXTnhtZFdra2ZpZXRmRXU?oc=5","date":"2025-10-16","type":"trial","source":"Fierce Biotech","summary":"Praxis erases doubts with phase 3 wins in essential tremor, sending shares soaring - Fierce Biotech","headline":"Praxis erases doubts with phase 3 wins in essential tremor, sending shares soaring","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivgFBVV95cUxNR2xnM0NlU1lFRGkwZUsycVF1VzNXcmcyTkdacFNyZFYxdTZtVDFncUtZOUVIaHA4Zlo3THFXWWM0VkFqdU1yekpONTZJalNVMHBsRFpsWldFXzJFYlQtd2F5VW5COHdVR1Nfd2dCSFl3VlJUTjEzWFZRS1llUTFkend2NkRwQ2tqVTNQSVlZRDdXQTBNc0VnNk9PVkJab0xubmNYQW9GYnhCeHYyQTAwMjg5MWFqU2c4TXVwLVlB?oc=5","date":"2025-10-16","type":"trial","source":"Stock Titan","summary":"Praxis Precision Medicines Reports 4.3‑pt M-ADL11 Gain in Phase 3 | PRAX Stock News - Stock Titan","headline":"Praxis Precision Medicines Reports 4.3‑pt M-ADL11 Gain in Phase 3 | PRAX Stock News","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiU0FVX3lxTE1jeFFvQnhiSDZYQkM3VU15a0NiMTJOWk5lMkk4YlU3MU5TTDNXUDQ4QjlsYmZzOW1yZ3UtQmhMSkNvSGt0SVVIWktZSWhhSGlENVVr?oc=5","date":"2025-10-16","type":"regulatory","source":"FirstWord Pharma","summary":"Praxis soars on Phase III data, planned FDA filing for tremor drug - FirstWord Pharma","headline":"Praxis soars on Phase III data, planned FDA filing for tremor drug","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiowJBVV95cUxONy02cWRYc1Bfb20xVnl5NHcwT2xpYUp5dFROenBfZFFKNElRQzc3emItWTQ2OUZlNnl0ZTJiVFZjcDZOaHRoNTRISGYzQzQ0MHprVUlBOXVjdW1jUGxyVEQ1TUpRa1RQTlQ1V29md0lfckY2MldGOHNHcXd3U0x6Z3Q5NXJvajB5b1U0OVkwUExGWDJtaVVUOGJveEZJTVFiZ0VuWDY0c0dBeENlVDdrZGVBTTlrLWRqUS05SEMyR3dBZnVWS2lIT09QZjkwSWVlMVliXzJtbFV6dGRZLWIwR08yTklaNW9sd19yRFVPQXBQOGhwMnplendwMFhOMmpjMWphOS1PMHppbE0zNU1DNndERUc4d2xUWWJSZDFwTkVHOGM?oc=5","date":"2025-09-29","type":"pipeline","source":"businesswire.com","summary":"ReCode Therapeutics Announces Over $29 Million in Additional Financing to Advance Genetic Medicines Pipeline and Provides Corporate Update - businesswire.com","headline":"ReCode Therapeutics Announces Over $29 Million in Additional Financing to Advance Genetic Medicines Pipeline and Provide","sentiment":"neutral"}],"patents":[],"drugCount":3,"phaseCounts":{"phase_1":2,"phase_3":1},"enrichmentLevel":0,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}